1. V. P. Shah, K. K. Midha, and S. V. Dighe. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies (conference report). Eur. J. Drug Metab Pharmacokinet. 16(4):249–255 (1992).
2. V. P. Shah, K. K. Midha, J. W. A. Findlay, H. M. Hill, J. D. Hulse, I. J. McGilveray, G. McKay, K. J. Miller, R. N. Patnaik, M. L. Powell, A. Tonelli, C. T. Viswanathan, and A. Yacobi. Bioanalytical method validation—a revisit with a decade of progress. Pharm. Res. 17(12):1551–1557 (2000).
3. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation, US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Rockville, MD, 2001.
4. B. DeSilva, W. Smith, R. Weiner, M. Kelley, J. Smolec, B. Lee, M. Khan, R. Tacey, H. Hill, and A. Celniker. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11):1885–1900 (2003).
5. Food and Drug Administration. Draft Guidance for Industry: Safety Testing of Drug Metabolites, US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Rockville, MD, 2005.